Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Anthrax action shapes up

24.10.2001


Anthrax is under close scrutiny.
© AP/Fort Detrick, US Army


Washington’s Dirkin Senate Office gets a careful clean-up.
© AP/Kenneth Lambert


Researchers find two new leads for anti-anthrax drugs.

As fears over bioterrorism attacks spiral, researchers are making progress towards better anthrax drugs - but these are unlikely to reach the drugstore soon.

Of ten confirmed anthrax cases in the United States by Monday, four have been of the severe, inhaled form against which antibiotics often fail. By the time drugs destroy the bacteria responsible, Bacillus anthracis, the organisms have released enough lethal toxin to kill immune cells in the blood, causing fatal blood poisoning.



Two new discoveries lay the groundwork for drugs that could disable the toxin and, along with antibiotics, save lives.

John Young, of the University of Wisconsin in Madison, and his colleagues have pinpointed the protein, on the surface of human cells, which the anthrax toxin latches onto1. In the lab a synthetic version of this ’receptor’ mops up the poison and protects cells. "It serves as a decoy," Young explains.

Part of the toxin attaches to this receptor, punches a hole in the human cell membrane and injects another part, the ’lethal factor’, which destroys proteins in the cell. A second team, led by Robert Liddington of The Burnham Institute in La Jolla, California, have deduced the structure of this lethal factor2.

With a picture of how the toxin’s proteins attack cells, drug companies can search for chemicals that block their activity, the teams hope.

This promise is unlikely to be realized in time to help the current situation, Young and Liddington caution - most optimistic estimates are that improvements will be a year in the making. "We need to design drugs - not for this time round but for the next one," says Liddington.

Alternative medicine

The current crisis gives the hunt for effective treatments new urgency. What we have is no longer "state-of-the-art", says Richard Corlin, director of the American Medical Association in Chicago, Illinois. The latest work "will lead us to a better treatment", he agrees.

Excessive use of an existing antibiotic, ciprofloxacin, could create its own medical problems, Corlin warns. The drug destroys healthy bacteria in the body, so may leave people open to infection from other pathogens.

Overuse of antibiotics and failure to complete the 60-day course virtually "guarantee the emergence of antibiotic resistant strains" of these pathogenic bacteria, he says, making such infections difficult to treat.

Bioterrorists could potentially engineer antibiotic-resistant anthrax. Manufacturing bacteria able to withstand toxin-targeted drugs would be "almost impossible", says John Collier of Harvard Medical School, who contributed to both studies. It would require expert biochemical knowledge to alter specific protein shapes and interactions.

The anthrax vaccine is also problematic. Developed in the 1960s, it involves injecting a crude mix of the toxin’s protein components to stimulate resistance. Vaccination requires six shots and regular boosters. The vaccine is currently produced only in sufficient quantities for the US military.

Several groups are designing more effective versions using purified proteins, explains anthrax researcher Stephen Leppla of the National Institute of Dental and Craniofacial Reseach in Bethesda, Maryland. These are easily administered and produce long-lasting immunity. "Before too long, we’ll have it," he predicts.

Ultimately, we need a whole new arsenal to fight anthrax, says Collier - a new antibiotic, a safe, efficient vaccine, and drugs against toxins. Realizing this goal requires further funding for research and fast-track approval of candidate drugs, he suggests.

Meanwhile most people agree that heightened awareness remains the best form of defence, catching early, cold-like symptoms in time for the disease to be treated. "The key thing is an appropriate degree of surveillance," says Corbin.

Spore show

Anthrax spores, the persistent, dormant form of the bacterium, can cause infection through the skin and intestine, but inhalation is the most dangerous - around 90% of cases result in death.

Turning anthrax into an effective bioweapon is technically difficult - spores must be milled down into a very fine powder (less than 5 micrometres in diameter) for them to reach the depths of the lungs in sufficient quantities to cause infection. A dose of around 10,000 spores is thought to cause a lethal infection.

Spores sent in letters to media and political organizations in the United States had produced ten confirmed cases by the end of Monday, including one death. The deaths of two more postal workers have been linked to the disease. The source of the letters has not yet been found, and the United States is offering a $1-million reward for information leading to the identification of those responsible.

References
  1. Bradley, K.A., Mogridge, J., Mourez, M., Collier, R.J. & Young, J.A.T. Identification of the cellular receptor for the anthrax toxin. Nature, (2001).

  2. Panniter, A. et al. Crystal structure of the anthrax lethal factor. Nature, (2001).


HELEN PEARSON | Nature News Service
Further information:
http://www.nature.com/nsu/011025/011025-9.html
http://www.nature.com/nsu/

More articles from Health and Medicine:

nachricht Custom-tailored strategy against glioblastomas
26.09.2016 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New leukemia treatment offers hope
23.09.2016 | King Abdullah University of Science and Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New welding process joins dissimilar sheets better

Friction stir welding is a still-young and thus often unfamiliar pressure welding process for joining flat components and semi-finished components made of light metals.
Scientists at the University of Stuttgart have now developed two new process variants that will considerably expand the areas of application for friction stir welding.
Technologie-Lizenz-Büro (TLB) GmbH supports the University of Stuttgart in patenting and marketing its innovations.

Friction stir welding is a still-young and thus often unfamiliar pressure welding process for joining flat components and semi-finished components made of...

Im Focus: First quantum photonic circuit with electrically driven light source

Optical quantum computers can revolutionize computer technology. A team of researchers led by scientists from Münster University and KIT now succeeded in putting a quantum optical experimental set-up onto a chip. In doing so, they have met one of the requirements for making it possible to use photonic circuits for optical quantum computers.

Optical quantum computers are what people are pinning their hopes on for tomorrow’s computer technology – whether for tap-proof data encryption, ultrafast...

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

Im Focus: Complex hardmetal tools out of the 3D printer

For the first time, Fraunhofer IKTS shows additively manufactured hardmetal tools at WorldPM 2016 in Hamburg. Mechanical, chemical as well as a high heat resistance and extreme hardness are required from tools that are used in mechanical and automotive engineering or in plastics and building materials industry. Researchers at the Fraunhofer Institute for Ceramic Technologies and Systems IKTS in Dresden managed the production of complex hardmetal tools via 3D printing in a quality that are in no way inferior to conventionally produced high-performance tools.

Fraunhofer IKTS counts decades of proven expertise in the development of hardmetals. To date, reliable cutting, drilling, pressing and stamping tools made of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

European Health Forum Gastein 2016 kicks off today

28.09.2016 | Event News

Laser use for neurosurgery and biofabrication - LaserForum 2016 focuses on medical technology

27.09.2016 | Event News

Experts from industry and academia discuss the future mobile telecommunications standard 5G

23.09.2016 | Event News

 
Latest News

A perfect sun-storm

28.09.2016 | Earth Sciences

New welding process joins dissimilar sheets better

28.09.2016 | Power and Electrical Engineering

European Health Forum Gastein 2016 kicks off today

28.09.2016 | Event News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>